Quotidian Technical Highlights on Selected Healthcare Stocks -- Atossa Genetics, Palatin Technologies, Adamis Pharma, and Perrigo

NEW YORK, Feb. 23, 2018 /PRNewswire/ -- WallStEquities.com strives to bring the best free research to the investment community.  Today we are offering reports on ATOS, PTN, ADMP, and PRGO which can be accessed for free by signing up to www.wallstequities.com/registration. Today, WallStEquities.com observes the recent performance of Atossa Genetics Inc. (NASDAQ: ATOS), Palatin Technologies Inc. (NYSEAMER: PTN), Adamis Pharmaceuticals Corp. (NASDAQ: ADMP), and Perrigo Co. PLC (NYSE: PRGO). Companies in the Healthcare sector provide medical services, manufacture medical equipment or drugs, provide medical insurance, or otherwise facilitate the provision of healthcare to patients. All you have to do is sign up today for this free limited time offer by clicking the link below.

www.wallstequities.com/registration

Atossa Genetics

On Thursday, shares in Seattle, Washington headquartered Atossa Genetics Inc. recorded a trading volume of 2.03 million shares. The stock ended at $0.54, plummeting 7.88% from the last trading session. The Company's shares have surged 64.73% in the last month and 51.89% over the previous three months. The stock is trading above its 50-day and 200-day moving averages by 34.17% and 21.49%, respectively. Furthermore, shares of Atossa Genetics have a Relative Strength Index (RSI) of 51.11. 

On January 26^th, 2018, research firm Maxim Group initiated a 'Buy' rating on the Company's stock, with a target price of $2 per share.

On February 01^st, 2018, Atossa Genetics announced additional findings from the Phase-1 study of its proprietary oral Endoxifen, an active metabolite of the FDA-approved drug tamoxifen: (i) the median time for patients in the study to reach the steady-state serum levels of Endoxifen while taking daily doses of oral Endoxifen was seven days, and (ii) the median time for patients in the study to reach the maximum serum level of Endoxifen after taking oral Endoxifen was ranged from four to eight hours, depending on dose.  Get the full research report on ATOS for free by clicking below at:

www.wallstequities.com/registration/?symbol=ATOS

Palatin Technologies

Cranbury, New Jersey-based Palatin Technologies Inc.'s stock finished yesterday's session 0.51% lower at $0.98 with a total trading volume of 899,442 shares. The Company's shares have gained 1.67% in the last month, 11.65% over the previous three months, and 156.58% over the past year. The stock is trading above its 50-day and 200-day moving averages by 7.82% and 50.24%, respectively. Furthermore, shares of Palatin Technologies, which develops targeted, receptor-specific peptide therapeutics for the treatment of various diseases in the US, have an RSI of 57.78. 

On February 05^th, 2018, Palatin Technologies announced that the first healthy subjects have been dosed in a Phase-1 clinical study of PL-8177. The Phase 1 study is a randomized, double-blind, placebo-controlled, single and multiple ascending dose study intended to evaluate the safety and tolerability of PL-8177 administered via subcutaneous injection. The study is designed to enroll up to 52 healthy volunteers. Top-line data is currently expected in Q3 2018. The free technical report on PTN can be accessed at:

www.wallstequities.com/registration/?symbol=PTN

Adamis Pharmaceuticals

On Thursday, shares in San Diego, California headquartered Adamis Pharmaceuticals Corp. dropped 9.73%, ending the day at $2.55. The stock recorded a trading volume of 1.97 million shares, which was above its three months average volume of 706,200 shares. The Company's shares are trading 37.37% below their 50-day moving average. Moreover, shares of Adamis Pharma, which develops and commercializes products in the therapeutic areas of allergy and respiratory disease in the US, have an RSI of 26.27. 

On February 12^th, 2018, Adamis Pharma ("ADMP") announced that the US FDA has accepted for review the Company's supplemental New Drug Application for its low dose Symjepi^TM product candidate for the emergency treatment of anaphylaxis. On February 09^th, 2018, ADMP received FDA correspondence indicating that no potential review issues were identified, and if no major deficiencies were identified in their continued review, they are targeting September 03^rd, 2018 to communicate proposed labeling and, if necessary, any postmarketing requirement/commitment requests. Sign up for free on Wall St. Equities and claim the latest report on ADMP at:

www.wallstequities.com/registration/?symbol=ADMP

Perrigo

Dublin, Ireland headquartered Perrigo Co. PLC's shares ended the day 0.03% lower at $87.07 with a total trading volume of 682,845 shares. The stock has gained 2.19% over the previous three months and 3.54% over the past year. The Company's shares are trading 6.76% above their 200-day moving average. Additionally, shares of Perrigo have an RSI of 45.19. 

On February 15^th, 2018, Perrigo announced that its Board of Directors declared a quarterly dividend of $0.19 per share, payable on March 20^th, 2018, to shareholders of record on March 02^nd, 2018. See the free research coverage on PRGO at:

www.wallstequities.com/registration/?symbol=PRGO

Wall St. Equities:

Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

WSE has not been compensated; directly or indirectly; for producing or publishing this document. 

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  

NO WARRANTY

WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit https://wallstequities.com/legal-disclaimer/

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: [email protected]
Phone number: +21-32-044-483
Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Wall St. Equities